for a 2% improvement and tolerate side effects and dwindling efficacy. Provenge by DNDN was approved with a 30% efficacy for $93,000 but the stock went from $40 to $1.
after an equal number dropped out because of side effects. Even worse is the fact that the 2% improvement quickly wore off. Sounds like snake oil.
and there is no drug company with less insider share ownership than VRTX.
Are consumers finally fed up with Apple's high profit margins?
at a cost of $300,000 per year per patient after 15 other patients dropped out of the study due to adverse side effects. Even worse is the 2 to 3% improvement quickly wore off.
if they could get rid of the side effects so that half the patients wouldn't drop out.
This is either corruption gone wild or a joke to approve this application which has no statistical efficacy.
Sounds like a rounding error.
and Steve Wynn is the best in the business.
without collapsing in inappropriate cheap stock options to its insiders.
and some side effects where half the patients drop out.
and it wears off quickly and even has many side effects that cause patients to drop out.
and who does this money losing company have a market cap of $30 Billion. Perhaps it should be $3 Billion.
and it starts to decline from there and there are side effects. After the treatment stops the patient goes back to zero but the side effects such as liver enzymes start to improve.